L L Koh1, S O'Rourke2, M Brennan3, L Clooney4, M Cafferkey1, N McCallion5, R J Drew6,7,8. 1. Perdana University Royal College of Surgeons in Ireland, Kuala Lumpar, Malaysia. 2. Irish Meningitis and Sepsis Reference Laboratory, Children's University Hospital Temple Street, Dublin 1, Ireland. 3. Department of Midwifery, Rotunda Hospital, Dublin 1, Ireland. 4. Department of Pharmacy, Rotunda Hospital, Dublin 1, Ireland. 5. Department of Neonatology, Rotunda Hospital, Dublin 1, Ireland. 6. Irish Meningitis and Sepsis Reference Laboratory, Children's University Hospital Temple Street, Dublin 1, Ireland. rdrew@rotunda.ie. 7. Department of Microbiology, Rotunda Hospital, Dublin 1, Ireland. rdrew@rotunda.ie. 8. Department of Microbiology, Royal College of Surgeons in Ireland, Dublin 2, Ireland. rdrew@rotunda.ie.
Abstract
BACKGROUND: Both Staphylococcus aureus and coagulase negative Staphylococci are common causes of late-onset neonatal sepsis in the neonatal intensive care unit (NICU), usually relating to intravascular access device infections. AIMS: This project aimed to review the impact on antimicrobial treatment and clinical outcome in the NICU setting, of the introduction of the Xpert MRSA/SA BC test (Cepheid, USA) for the identification of staphylococci in blood cultures. METHODS: A retrospective audit was carried out of the pre- and post-intervention periods; the intervention was the introduction of the Xpert MRSA/SA BC test. RESULTS: In total, 88 neonates had positive blood cultures with Staphylococcus spp., comprising 42 neonates in the pre-intervention and 46 in the post-intervention groups. The pre-intervention group had a higher birth weight (1.541 kg vs. 1.219 kg, p = 0.05) and higher platelet count (288 vs. 224 × 109/L, p = 0.05). There was a trend towards a shorter duration of antimicrobial therapy in term infants and in the length of admission; however, this was not statistically significant (p = 0.2). All of the nine infants post-intervention with significant bacteraemia (S. aureus =3, CoNS =6) were changed to the optimal antimicrobial at the time the result was available. CONCLUSIONS: This study shows that the introduction of the Xpert MRSA/SA BC test can lead to a reduction in the length of admission and duration of antimicrobials in term infants; however, the difference was not statistically significant. All nine infants with clinically significant bacteraemia were treated with the appropriate antimicrobial when the Xpert MRSA/SA BC test result was available.
BACKGROUND: Both Staphylococcus aureus and coagulase negative Staphylococci are common causes of late-onset neonatal sepsis in the neonatal intensive care unit (NICU), usually relating to intravascular access device infections. AIMS: This project aimed to review the impact on antimicrobial treatment and clinical outcome in the NICU setting, of the introduction of the Xpert MRSA/SA BC test (Cepheid, USA) for the identification of staphylococci in blood cultures. METHODS: A retrospective audit was carried out of the pre- and post-intervention periods; the intervention was the introduction of the Xpert MRSA/SA BC test. RESULTS: In total, 88 neonates had positive blood cultures with Staphylococcus spp., comprising 42 neonates in the pre-intervention and 46 in the post-intervention groups. The pre-intervention group had a higher birth weight (1.541 kg vs. 1.219 kg, p = 0.05) and higher platelet count (288 vs. 224 × 109/L, p = 0.05). There was a trend towards a shorter duration of antimicrobial therapy in term infants and in the length of admission; however, this was not statistically significant (p = 0.2). All of the nine infants post-intervention with significant bacteraemia (S. aureus =3, CoNS =6) were changed to the optimal antimicrobial at the time the result was available. CONCLUSIONS: This study shows that the introduction of the Xpert MRSA/SA BC test can lead to a reduction in the length of admission and duration of antimicrobials in term infants; however, the difference was not statistically significant. All nine infants with clinically significant bacteraemia were treated with the appropriate antimicrobial when the Xpert MRSA/SA BC test result was available.
Entities:
Keywords:
Bacteraemia; GeneXpert; MRSA; Xpert MRSA/SA BC
Authors: Anthony R Burrell; Mary-Louise McLaws; Mary Fullick; Rosemary B Sullivan; Doungkamol Sindhusake Journal: Med J Aust Date: 2016-02-01 Impact factor: 7.738
Authors: Stefania Vergnano; Esse Menson; Nigel Kennea; Nick Embleton; Alison Bedford Russell; Timothy Watts; Michael J Robinson; Andrew Collinson; Paul T Heath Journal: Arch Dis Child Fetal Neonatal Ed Date: 2010-09-27 Impact factor: 5.747
Authors: Nila J Dharan; Robert Blakemore; Alex Sloutsky; Devinder Kaur; Richard C Alexander; Minoo Ghajar; Kimberlee A Musser; Vincent E Escuyer; Marie-Claire Rowlinson; Susanne Crowe; Rafael Laniado-Laborin; Eloise Valli; Pamela Nabeta; Pamela Johnson; David Alland Journal: BMC Infect Dis Date: 2016-12-20 Impact factor: 3.090
Authors: Joshua T Thaden; Jessica E Ericson; Heather Cross; Stephen P Bergin; Julia A Messina; Vance G Fowler; Daniel K Benjamin; Reese H Clark; Christoph P Hornik; P Brian Smith Journal: Pediatr Infect Dis J Date: 2015-11 Impact factor: 3.806
Authors: Yuliya Zboromyrska; Cristina De la Calle; Marcelo Soto; Laura Sampietro-Colom; Alex Soriano; Míriam José Alvarez-Martínez; Manel Almela; Francesc Marco; Ruth Arjona; Nazaret Cobos-Trigueros; Laura Morata; José Mensa; José Antonio Martínez; Aurea Mira; Jordi Vila Journal: PLoS One Date: 2016-08-29 Impact factor: 3.240